APO Research
Talk to an analyst

APO RESEARCH · REPORT

Live Attenuated Vaccine for Chickenpox

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Live Attenuated Vaccine for Chickenpox Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025198 pages

Choose your research edition.

Industry ResearchLive Attenuated Vaccine for Chickenpox Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Live Attenuated Vaccine for Chickenpox Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Live Attenuated Vaccine for Chickenpox Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Live Attenuated Vaccine for Chickenpox Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Live Attenuated Vaccine for Chickenpox Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Live Attenuated Vaccine for Chickenpox market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Live Attenuated Vaccine for Chickenpox is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Live Attenuated Vaccine for Chickenpox is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Live Attenuated Vaccine for Chickenpox is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Live Attenuated Vaccine for Chickenpox is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Live Attenuated Vaccine for Chickenpox include GSK, BCHT, Biken, Green Cross, Keygen, Merck & Co lnc, Sanofi Pasteur, Beijing Institute of Biological Products Co., Ltd and Chengdu Institute of Biological Products Co., Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Live Attenuated Vaccine for Chickenpox market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Live Attenuated Vaccine for Chickenpox and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Live Attenuated Vaccine for Chickenpox sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Live Attenuated Vaccine for Chickenpox market size, projected growth trends, production technologies, key applications, and end-use industries.

Live Attenuated Vaccine for Chickenpox Segment by Company

GSK

BCHT

Biken

Green Cross

Keygen

Merck & Co lnc

Sanofi Pasteur

Beijing Institute of Biological Products Co., Ltd

Chengdu Institute of Biological Products Co., Ltd

Kexing (Dalian) Vaccine Technology Co., Ltd

Shanghai Rongsheng Biopharmaceutical Co., Ltd

Shanghai Institute of Biological Products Co., Ltd

Changchun Baike Biotechnology Co., Ltd

Changchun Qijian Biological Products Co., Ltd

Live Attenuated Vaccine for Chickenpox Segment by Type

Child

Adult

Live Attenuated Vaccine for Chickenpox Segment by Application

Hospital

Clinic

Live Attenuated Vaccine for Chickenpox Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Vaccine for Chickenpox market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Vaccine for Chickenpox and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Vaccine for Chickenpox.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Live Attenuated Vaccine for Chickenpox market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Live Attenuated Vaccine for Chickenpox manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Live Attenuated Vaccine for Chickenpox in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Live Attenuated Vaccine for Chickenpox in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Live Attenuated Vaccine for Chickenpox Industry Trends Table 2. Live Attenuated Vaccine for Chickenpox Industry Drivers Table 3. Live Attenuated Vaccine for Chickenpox Industry Opportunities and Challenges Table 4. Live Attenuated Vaccine for Chickenpox Industry Restraints Table 5. Global Live Attenuated Vaccine for Chickenpox Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Live Attenuated Vaccine for Chickenpox Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Manufacturers Table 9. Global Live Attenuated Vaccine for Chickenpox Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Live Attenuated Vaccine for Chickenpox Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Live Attenuated Vaccine for Chickenpox Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Live Attenuated Vaccine for Chickenpox Manufacturers, Product Type & Application Table 13. Global Live Attenuated Vaccine for Chickenpox Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Live Attenuated Vaccine for Chickenpox by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Child Table 17. Major Manufacturers of Adult Table 18. Global Live Attenuated Vaccine for Chickenpox Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Live Attenuated Vaccine for Chickenpox Sales by Type (2021-2026) & (K Units) Table 20. Global Live Attenuated Vaccine for Chickenpox Sales by Type (2027-2032) & (K Units) Table 21. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Type (2021-2026) Table 22. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Type (2027-2032) Table 23. Global Live Attenuated Vaccine for Chickenpox Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Live Attenuated Vaccine for Chickenpox Revenue by Type (2021-2026) & (K Units) Table 25. Global Live Attenuated Vaccine for Chickenpox Revenue by Type (2027-2032) & (K Units) Table 26. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Type (2021-2026) Table 27. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Clinic Table 30. Global Live Attenuated Vaccine for Chickenpox Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 31. Global Live Attenuated Vaccine for Chickenpox Sales by Application (2021-2026) & (K Units) Table 32. Global Live Attenuated Vaccine for Chickenpox Sales by Application (2027-2032) & (K Units) Table 33. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Application (2021-2026) Table 34. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Application (2027-2032) Table 35. Global Live Attenuated Vaccine for Chickenpox Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Live Attenuated Vaccine for Chickenpox Revenue by Application (2021-2026) & (K Units) Table 37. Global Live Attenuated Vaccine for Chickenpox Revenue by Application (2027-2032) & (K Units) Table 38. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Application (2021-2026) Table 39. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Application (2027-2032) Table 40. Global Live Attenuated Vaccine for Chickenpox Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 41. Global Live Attenuated Vaccine for Chickenpox Sales by Region (2021-2026) & (K Units) Table 42. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Region (2021-2026) Table 43. Global Live Attenuated Vaccine for Chickenpox Sales Forecasted by Region (2027-2032) & (K Units) Table 44. Global Live Attenuated Vaccine for Chickenpox Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Live Attenuated Vaccine for Chickenpox Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 46. North America Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2026) & (K Units) Table 47. North America Live Attenuated Vaccine for Chickenpox Sales by Country (2027-2032) & (K Units) Table 48. Europe Live Attenuated Vaccine for Chickenpox Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. Europe Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2026) & (K Units) Table 50. Europe Live Attenuated Vaccine for Chickenpox Sales by Country (2027-2032) & (K Units) Table 51. Asia Pacific Live Attenuated Vaccine for Chickenpox Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Asia Pacific Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2026) & (K Units) Table 53. Asia Pacific Live Attenuated Vaccine for Chickenpox Sales by Country (2027-2032) & (K Units) Table 54. South America, Middle East and Africa Live Attenuated Vaccine for Chickenpox Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. South America, Middle East and Africa Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2026) & (K Units) Table 56. South America, Middle East and Africa Live Attenuated Vaccine for Chickenpox Sales by Country (2027-2032) & (K Units) Table 57. Global Live Attenuated Vaccine for Chickenpox Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Live Attenuated Vaccine for Chickenpox Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Live Attenuated Vaccine for Chickenpox Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Region (2021-2026) Table 61. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Region (2027-2032) Table 62. GSK Company Information Table 63. GSK Business Overview Table 64. GSK Live Attenuated Vaccine for Chickenpox Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. GSK Live Attenuated Vaccine for Chickenpox Product Portfolio Table 66. GSK Recent Development Table 67. BCHT Company Information Table 68. BCHT Business Overview Table 69. BCHT Live Attenuated Vaccine for Chickenpox Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. BCHT Live Attenuated Vaccine for Chickenpox Product Portfolio Table 71. BCHT Recent Development Table 72. Biken Company Information Table 73. Biken Business Overview Table 74. Biken Live Attenuated Vaccine for Chickenpox Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Biken Live Attenuated Vaccine for Chickenpox Product Portfolio Table 76. Biken Recent Development Table 77. Green Cross Company Information Table 78. Green Cross Business Overview Table 79. Green Cross Live Attenuated Vaccine for Chickenpox Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Green Cross Live Attenuated Vaccine for Chickenpox Product Portfolio Table 81. Green Cross Recent Development Table 82. Keygen Company Information Table 83. Keygen Business Overview Table 84. Keygen Live Attenuated Vaccine for Chickenpox Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Keygen Live Attenuated Vaccine for Chickenpox Product Portfolio Table 86. Keygen Recent Development Table 87. Merck & Co lnc Company Information Table 88. Merck & Co lnc Business Overview Table 89. Merck & Co lnc Live Attenuated Vaccine for Chickenpox Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Merck & Co lnc Live Attenuated Vaccine for Chickenpox Product Portfolio Table 91. Merck & Co lnc Recent Development Table 92. Sanofi Pasteur Company Information Table 93. Sanofi Pasteur Business Overview Table 94. Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Product Portfolio Table 96. Sanofi Pasteur Recent Development Table 97. Beijing Institute of Biological Products Co., Ltd Company Information Table 98. Beijing Institute of Biological Products Co., Ltd Business Overview Table 99. Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 101. Beijing Institute of Biological Products Co., Ltd Recent Development Table 102. Chengdu Institute of Biological Products Co., Ltd Company Information Table 103. Chengdu Institute of Biological Products Co., Ltd Business Overview Table 104. Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 106. Chengdu Institute of Biological Products Co., Ltd Recent Development Table 107. Kexing (Dalian) Vaccine Technology Co., Ltd Company Information Table 108. Kexing (Dalian) Vaccine Technology Co., Ltd Business Overview Table 109. Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 111. Kexing (Dalian) Vaccine Technology Co., Ltd Recent Development Table 112. Shanghai Rongsheng Biopharmaceutical Co., Ltd Company Information Table 113. Shanghai Rongsheng Biopharmaceutical Co., Ltd Business Overview Table 114. Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 116. Shanghai Rongsheng Biopharmaceutical Co., Ltd Recent Development Table 117. Shanghai Institute of Biological Products Co., Ltd Company Information Table 118. Shanghai Institute of Biological Products Co., Ltd Business Overview Table 119. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 121. Shanghai Institute of Biological Products Co., Ltd Recent Development Table 122. Changchun Baike Biotechnology Co., Ltd Company Information Table 123. Changchun Baike Biotechnology Co., Ltd Business Overview Table 124. Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 126. Changchun Baike Biotechnology Co., Ltd Recent Development Table 127. Changchun Qijian Biological Products Co., Ltd Company Information Table 128. Changchun Qijian Biological Products Co., Ltd Business Overview Table 129. Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 131. Changchun Qijian Biological Products Co., Ltd Recent Development Table 132. Key Raw Materials Table 133. Raw Materials Key Suppliers Table 134. Live Attenuated Vaccine for Chickenpox Distributors List Table 135. Live Attenuated Vaccine for Chickenpox Customers List Table 136. Research Programs/Design for This Report Table 137. Authors List of This Report Table 138. Secondary Sources Table 139. Primary Sources List of Figures Figure 1. Live Attenuated Vaccine for Chickenpox Product Image Figure 2. Global Live Attenuated Vaccine for Chickenpox Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Live Attenuated Vaccine for Chickenpox Market Size (2021-2032) & (US$ Million) Figure 4. Global Live Attenuated Vaccine for Chickenpox Sales (2021-2032) & (K Units) Figure 5. Global Live Attenuated Vaccine for Chickenpox Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Live Attenuated Vaccine for Chickenpox Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Child Image Figure 9. Adult Image Figure 10. Global Live Attenuated Vaccine for Chickenpox Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Live Attenuated Vaccine for Chickenpox Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Type (2021-2032) Figure 13. Global Live Attenuated Vaccine for Chickenpox Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Clinic Image Figure 18. Global Live Attenuated Vaccine for Chickenpox Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global Live Attenuated Vaccine for Chickenpox Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Application (2021-2032) Figure 21. Global Live Attenuated Vaccine for Chickenpox Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Application (2021-2032) Figure 24. North America Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 25. North America Live Attenuated Vaccine for Chickenpox Sales Market Share by Country (2021-2032) Figure 26. U.S. Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 27. Canada Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Mexico Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Europe Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Live Attenuated Vaccine for Chickenpox Sales Market Share by Country (2021-2032) Figure 31. Germany Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 32. France Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 33. U.K. Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Italy Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Netherlands Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Asia Pacific Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Live Attenuated Vaccine for Chickenpox Sales Market Share by Country (2021-2032) Figure 38. China Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Japan Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 40. South Korea Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Southeast Asia Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 42. India Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Australia Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South America, Middle East and Africa Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Live Attenuated Vaccine for Chickenpox Sales Market Share by Country (2021-2032) Figure 46. Brazil Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South Africa Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Saudi Arabia Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Turkey Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Argentina Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 51. UAE Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Egypt Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Chile Live Attenuated Vaccine for Chickenpox Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Global Live Attenuated Vaccine for Chickenpox Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Figure 57. North America Live Attenuated Vaccine for Chickenpox Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Figure 59. Europe Live Attenuated Vaccine for Chickenpox Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Live Attenuated Vaccine for Chickenpox Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Live Attenuated Vaccine for Chickenpox Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Live Attenuated Vaccine for Chickenpox Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Live Attenuated Vaccine for Chickenpox Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Child
  • Adult
Applications
  • Hospital
  • Clinic
Companies covered
  • GSK
  • BCHT
  • Biken
  • Green Cross
  • Keygen
  • Merck & Co lnc
  • Sanofi Pasteur
  • Beijing Institute of Biological Products Co., Ltd
  • Chengdu Institute of Biological Products Co., Ltd
  • Kexing (Dalian) Vaccine Technology Co., Ltd
  • Shanghai Rongsheng Biopharmaceutical Co., Ltd
  • Shanghai Institute of Biological Products Co., Ltd
  • Changchun Baike Biotechnology Co., Ltd
  • Changchun Qijian Biological Products Co., Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Live Attenuated Vaccine for Chickenpox Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Live Attenuated Vaccine for Chickenpox Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Live Attenuated Vaccine for Chickenpox Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Live Attenuated Vaccine for Chickenpox Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Live Attenuated Vaccine for Chickenpox Market Dynamics
  1. 2.1 Live Attenuated Vaccine for Chickenpox Industry Trends
  2. 2.2 Live Attenuated Vaccine for Chickenpox Industry Drivers
  3. 2.3 Live Attenuated Vaccine for Chickenpox Industry Opportunities and Challenges
  4. 2.4 Live Attenuated Vaccine for Chickenpox Industry Restraints
3 Live Attenuated Vaccine for Chickenpox Market by Manufacturers
  1. 3.1 Global Live Attenuated Vaccine for Chickenpox Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Live Attenuated Vaccine for Chickenpox Sales by Manufacturers (2021-2026)
  3. 3.3 Global Live Attenuated Vaccine for Chickenpox Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Live Attenuated Vaccine for Chickenpox Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Live Attenuated Vaccine for Chickenpox Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Live Attenuated Vaccine for Chickenpox Manufacturers, Product Type & Application
  7. 3.7 Global Live Attenuated Vaccine for Chickenpox Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Live Attenuated Vaccine for Chickenpox Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Live Attenuated Vaccine for Chickenpox Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Live Attenuated Vaccine for Chickenpox Tier 1, Tier 2, and Tier 3
4 Live Attenuated Vaccine for Chickenpox Market by Type
  1. 4.1 Live Attenuated Vaccine for Chickenpox Type Introduction
  2. 4.1.1 Child
  3. 4.1.2 Adult
  4. 4.2 Global Live Attenuated Vaccine for Chickenpox Sales by Type
  5. 4.2.1 Global Live Attenuated Vaccine for Chickenpox Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Live Attenuated Vaccine for Chickenpox Sales by Type (2021-2032)
  7. 4.2.3 Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Type (2021-2032)
  8. 4.3 Global Live Attenuated Vaccine for Chickenpox Revenue by Type
  9. 4.3.1 Global Live Attenuated Vaccine for Chickenpox Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Live Attenuated Vaccine for Chickenpox Revenue by Type (2021-2032)
  11. 4.3.3 Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Type (2021-2032)
5 Live Attenuated Vaccine for Chickenpox Market by Application
  1. 5.1 Live Attenuated Vaccine for Chickenpox Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Live Attenuated Vaccine for Chickenpox Sales by Application
  5. 5.2.1 Global Live Attenuated Vaccine for Chickenpox Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Live Attenuated Vaccine for Chickenpox Sales by Application (2021-2032)
  7. 5.2.3 Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Application (2021-2032)
  8. 5.3 Global Live Attenuated Vaccine for Chickenpox Revenue by Application
  9. 5.3.1 Global Live Attenuated Vaccine for Chickenpox Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Live Attenuated Vaccine for Chickenpox Revenue by Application (2021-2032)
  11. 5.3.3 Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Application (2021-2032)
6 Global Live Attenuated Vaccine for Chickenpox Sales by Region
  1. 6.1 Global Live Attenuated Vaccine for Chickenpox Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Live Attenuated Vaccine for Chickenpox Sales by Region (2021-2032)
  3. 6.2.1 Global Live Attenuated Vaccine for Chickenpox Sales by Region (2021-2026)
  4. 6.2.2 Global Live Attenuated Vaccine for Chickenpox Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Live Attenuated Vaccine for Chickenpox Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Live Attenuated Vaccine for Chickenpox Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Live Attenuated Vaccine for Chickenpox Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Live Attenuated Vaccine for Chickenpox Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Live Attenuated Vaccine for Chickenpox Revenue by Region
  1. 7.1 Global Live Attenuated Vaccine for Chickenpox Revenue by Region
  2. 7.1.1 Global Live Attenuated Vaccine for Chickenpox Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Live Attenuated Vaccine for Chickenpox Revenue by Region (2021-2026)
  4. 7.1.3 Global Live Attenuated Vaccine for Chickenpox Revenue by Region (2027-2032)
  5. 7.1.4 Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Live Attenuated Vaccine for Chickenpox Revenue (2021-2032)
  8. 7.2.2 North America Live Attenuated Vaccine for Chickenpox Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Live Attenuated Vaccine for Chickenpox Revenue (2021-2032)
  11. 7.3.2 Europe Live Attenuated Vaccine for Chickenpox Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Live Attenuated Vaccine for Chickenpox Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Live Attenuated Vaccine for Chickenpox Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Live Attenuated Vaccine for Chickenpox Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Live Attenuated Vaccine for Chickenpox Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GSK Live Attenuated Vaccine for Chickenpox Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 BCHT
  8. 8.2.1 BCHT Company Information
  9. 8.2.2 BCHT Business Overview
  10. 8.2.3 BCHT Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 BCHT Live Attenuated Vaccine for Chickenpox Product Portfolio
  12. 8.2.5 BCHT Recent Developments
  13. 8.3 Biken
  14. 8.3.1 Biken Company Information
  15. 8.3.2 Biken Business Overview
  16. 8.3.3 Biken Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Biken Live Attenuated Vaccine for Chickenpox Product Portfolio
  18. 8.3.5 Biken Recent Developments
  19. 8.4 Green Cross
  20. 8.4.1 Green Cross Company Information
  21. 8.4.2 Green Cross Business Overview
  22. 8.4.3 Green Cross Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Green Cross Live Attenuated Vaccine for Chickenpox Product Portfolio
  24. 8.4.5 Green Cross Recent Developments
  25. 8.5 Keygen
  26. 8.5.1 Keygen Company Information
  27. 8.5.2 Keygen Business Overview
  28. 8.5.3 Keygen Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Keygen Live Attenuated Vaccine for Chickenpox Product Portfolio
  30. 8.5.5 Keygen Recent Developments
  31. 8.6 Merck & Co lnc
  32. 8.6.1 Merck & Co lnc Company Information
  33. 8.6.2 Merck & Co lnc Business Overview
  34. 8.6.3 Merck & Co lnc Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck & Co lnc Live Attenuated Vaccine for Chickenpox Product Portfolio
  36. 8.6.5 Merck & Co lnc Recent Developments
  37. 8.7 Sanofi Pasteur
  38. 8.7.1 Sanofi Pasteur Company Information
  39. 8.7.2 Sanofi Pasteur Business Overview
  40. 8.7.3 Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Product Portfolio
  42. 8.7.5 Sanofi Pasteur Recent Developments
  43. 8.8 Beijing Institute of Biological Products Co., Ltd
  44. 8.8.1 Beijing Institute of Biological Products Co., Ltd Company Information
  45. 8.8.2 Beijing Institute of Biological Products Co., Ltd Business Overview
  46. 8.8.3 Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  48. 8.8.5 Beijing Institute of Biological Products Co., Ltd Recent Developments
  49. 8.9 Chengdu Institute of Biological Products Co., Ltd
  50. 8.9.1 Chengdu Institute of Biological Products Co., Ltd Company Information
  51. 8.9.2 Chengdu Institute of Biological Products Co., Ltd Business Overview
  52. 8.9.3 Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  54. 8.9.5 Chengdu Institute of Biological Products Co., Ltd Recent Developments
  55. 8.10 Kexing (Dalian) Vaccine Technology Co., Ltd
  56. 8.10.1 Kexing (Dalian) Vaccine Technology Co., Ltd Company Information
  57. 8.10.2 Kexing (Dalian) Vaccine Technology Co., Ltd Business Overview
  58. 8.10.3 Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  60. 8.10.5 Kexing (Dalian) Vaccine Technology Co., Ltd Recent Developments
  61. 8.11 Shanghai Rongsheng Biopharmaceutical Co., Ltd
  62. 8.11.1 Shanghai Rongsheng Biopharmaceutical Co., Ltd Company Information
  63. 8.11.2 Shanghai Rongsheng Biopharmaceutical Co., Ltd Business Overview
  64. 8.11.3 Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  66. 8.11.5 Shanghai Rongsheng Biopharmaceutical Co., Ltd Recent Developments
  67. 8.12 Shanghai Institute of Biological Products Co., Ltd
  68. 8.12.1 Shanghai Institute of Biological Products Co., Ltd Company Information
  69. 8.12.2 Shanghai Institute of Biological Products Co., Ltd Business Overview
  70. 8.12.3 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  72. 8.12.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
  73. 8.13 Changchun Baike Biotechnology Co., Ltd
  74. 8.13.1 Changchun Baike Biotechnology Co., Ltd Company Information
  75. 8.13.2 Changchun Baike Biotechnology Co., Ltd Business Overview
  76. 8.13.3 Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  78. 8.13.5 Changchun Baike Biotechnology Co., Ltd Recent Developments
  79. 8.14 Changchun Qijian Biological Products Co., Ltd
  80. 8.14.1 Changchun Qijian Biological Products Co., Ltd Company Information
  81. 8.14.2 Changchun Qijian Biological Products Co., Ltd Business Overview
  82. 8.14.3 Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  84. 8.14.5 Changchun Qijian Biological Products Co., Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Live Attenuated Vaccine for Chickenpox Value Chain Analysis
  2. 9.1.1 Live Attenuated Vaccine for Chickenpox Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Live Attenuated Vaccine for Chickenpox Production Mode & Process
  6. 9.2 Live Attenuated Vaccine for Chickenpox Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Live Attenuated Vaccine for Chickenpox Distributors
  9. 9.2.3 Live Attenuated Vaccine for Chickenpox Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst